What Key Growth Drivers Are Shaping The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Forecast Toward $35.81 Billion?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Present And Forecasted Size Of The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?
In recent times, the market size for b-cell maturation antigen (bcma) targeted therapies has seen substantial expansion. There is an anticipated growth from $12.17 billion in 2024 to $15.09 billion in 2025, with a compound annual growth rate (CAGR) of 24.0%. The notable growth in previous periods can be ascribed to the enhancing focus on hematologic malignancies, increasing contributions towards oncology research, rising necessity for personalized medicine, growing preference for CAR-T cell therapies, and increment in healthcare spending.
In the coming years, a steep upward curve in growth is anticipated for the b-cell maturation antigen (bcma) targeted therapies market. The evaluation predicts that by 2029, the market will reach a whopping $35.81 billion, with a compound annual growth rate (CAGR) of around 24.1%. The projected advancement over the forecast period owes to factors such as heightened attention towards cancer study, shifts in focus towards specific molecular markers, occurrences of various cancers, a boost in biotech financing, and the escalating application of cell and gene therapies. Upcoming major trends to watch out for include the pioneering CRISPR technology, progression in gene-editing methodologies, the next-generation advancements in car-t cell therapies, improvement in targeted antibody-drug conjugates, and the creation of readily available treatments.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20718&type=smp
Which Market Dynamics Are Playing A Critical Role In The Growth Of The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?
The upward trend in multiple myeloma cases anticipates driving the expansion of the B-cell maturation antigen (BCMA) targeted therapies market. Multiple myeloma, a cancer type that predominantly affects plasma cells integral to the immune system for antibody production, is on the rise. This surge can be ascribed to various factors such as a growing aging population, enhanced diagnostic abilities, and disparities in access to healthcare. BCMA targeted therapies, vital for treating multiple myeloma, focus on eradicating malignant plasma cells expressing BCMA, thus providing a potentially efficacious and focused treatment method. The American Cancer Society, a professional organization based in the U.S., reported around 35,780 newly diagnosed multiple myeloma cases in the U.S. in August 2024, characterizing 19,520 cases in men and 16,260 cases in women. An estimated 12,540 deaths, inclusive of 7,020 men and 5,520 women, are also forecasted. Hence, the escalating number of multiple myeloma incidences is fuelling the b-cell maturation antigen (BCMA) targeted therapies market’s development.
What Are The Key Segment Trends Observed In The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?
The b-cell maturation antigen (bcma) targeted therapiesmarket covered in this report is segmented –
1) By Product Type: Antibody Drug Conjugates; Chimeric Antigen Receptor T (CAR-T)-Cell Therapy; Bispecific Antibodies
2) By Indication Type: Acute Lymphoblastic Leukemia; Multiple Myeloma
3) By End User: Hospitals; Specialty Clinics; Home Care Settings
Subsegments:
1) By Antibody Drug Conjugates: BCMA-Targeted ADCs (Antibody-Drug Conjugates); Linker-Payload Technology-Based BCMA ADCs
2) By Chimeric Antigen Receptor T (CAR-T)-Cell Therapy: BCMA CAR-T Cells (Autologous); Allogeneic BCMA CAR-T Cells
3) By Bispecific Antibodies: BCMA x CD3 Bispecific Antibodies; BCMA x CD28 Bispecific Antibodies
Which Disruptive Trends Are Driving Change Across The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?
Major corporations active in the B-cell maturation antigen (BCMA) targeted therapies market are emphasizing the invention of innovative therapies like CAR-T cell therapy to enhance the precision and effectiveness of cancer cell targeting. CAR-T cell therapy is an immunotherapy form that modifies a patient’s T cells to express chimeric antigen receptors (CARs) for targeting and eliminating cancer cells. For instance, in April 2024, Johnson & Johnson, a pharmaceutical corporation based in the USA, got approval from the U.S. Food and Drug Administration (FDA) for CARVYKTI. CARVYKTI (ciltacabtagene autoleucel) is a BCMA-targeted, gene-altered autologous T-cell immunotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma who have previously undergone at least one therapy line and are resistant to lenalidomide.
Who Are The Leading Companies Driving The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market?
Major companies operating in the B-cell maturation antigen (BCMA) targeted therapies market are Bristol Myers Squibb Company, Novartis, GlaxoSmithKline (GSK), Takeda Pharmaceutical Company Limited, Amgen Inc, Regeneron Pharmaceuticals, Beigene, Arcellx Inc, Poseida Therapeutics, Legend Biotech Corporation, Cartesian Therapeutics, Juno Therapeutics, Sutro Biopharma Inc, CARsgen Therapeutics, Precision BioSciences, Eureka Therapeutics Inc, Cellectis, Teneobio Inc., Janssen Pharmaceuticals Companies, Allogene Therapeutics, Affimed, Bluebird Bio Inc.
Access The Complete Report Here:
Which Region Is Forecasted To Lead The B-Cell Maturation Antigen (BCMA) Targeted Therapies Market In The Coming Years?
North America was the largest region in the B-cell maturation antigen (BCMA) targeted therapies market in 2024. The regions covered in the B-cell maturation antigen (BCMA) targeted therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=20718&type=smp
Browse Through More Reports Similar to the Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market 2025, By The Business Research Company
Diffuse Large B Cell Lymphoma Therapeutics Global Market Report 2025
Brain Tumor Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report
Tumor Ablation Therapy Devices Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
